New BPA for vafseo and auryxia
Active Awarded Last action
- Contract number
- 36E79725A0015
- Awardee
-
Akebia Therapeutics, Inc. UEI YCMLJAJDXWC3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 76% complete
- IDV ceiling
- $10,254,764.65
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Akebia Therapeutics, Inc. was awarded a single-award Blanket Purchase Agreement by the National Acquisition Center (NAC), a civilian federal agency, for the supply of pharmaceutical products under the General Services Administration's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). This BPA, which represents Exercise Option Year 1 of the original agreement (BPA 36E79725A0015), carries a ceiling value of $10,254,764.65 and extends through April 24, 2027, with an award date of April 25, 2025. The contract was awarded without a set-aside restriction, indicating full and open competition. No specific places of performance or detailed task order information were provided in the available documentation.
The BPA covers Akebia Therapeutics' commercial pharmaceutical offerings, specifically Vafseo and Auryxia, which are medications used in the treatment of iron deficiency and secondary hyperparathyroidism in chronic kidney disease patients, respectively. As a GSA Schedule-based indefinite delivery vehicle, this agreement establishes a framework under which authorized federal agencies may place orders at established pricing without requiring new competitive solicitations for each purchase. The continuation of this BPA into its first option year demonstrates the National Acquisition Center's ongoing requirement for these specialized pharmaceutical products to support federal healthcare programs and beneficiaries.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0015?
36E79725A0015 was awarded to Akebia Therapeutics, Inc. by National Acquisition Center (Headquarters) on April 25, 2025.
How much is contract 36E79725A0015 worth?
36E79725A0015's own ceiling is $10,254,765.
Who can order from contract 36E79725A0015?
36E79725A0015 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0015 under another contract?
Yes. 36E79725A0015 is a blanket purchase agreement under 36F79721D0183, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0015 competed?
The extent of competition for 36E79725A0015 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV